--As part of China’s second booster campaign, Clover’s premium, broadly protective protein-based vaccine is now available in
Media Snippet accompanying this announcement is available by clicking on the image or link below:
“We are very proud to be delivering on our commitment to help protect the elderly and other vulnerable populations with our premium COVID-19 booster vaccine, and commencing the launch in
Clover’s COVID-19 vaccine was authorized for emergency use in
“We are thrilled to see our partnership with Clover reach this important milestone and to witness the moment its COVID-19 vaccine has become available to at-risk populations,” said Dr.
In a global Phase 2/3 clinical trial with over 30,000 participants across five countries, Clover’s COVID-19 vaccine achieved 100% efficacy against severe COVID-19 and hospitalization caused by all strains of SARS-CoV-2 circulating during the trial (LINK). In addition, a study embedded within this Phase 2/3 trial demonstrated that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received Clover’s vaccine, compared to households where the infected household member was not vaccinated (LINK). Finally, in a separate Phase 3 study, Clover’s COVID-19 vaccine demonstrated broad and robust cross-neutralization of multiple Omicron subvariants, including Omicron BA.1, BA.2, and BA.5, when it was administered as a third dose heterologous booster after two doses of inactivated vaccine—a response that was superior to a third dose of inactivated vaccine (LINK) (LINK). Analysis of the booster vaccine’s cross-neutralization of more recently circulating subvariants including Omicron BF.7, BQ.1.1 and BA.2.75 is consistent with prior data.
In addition to
About
For more information, please visit Clover's website: www.cloverbiopharma.com and follow the company on LinkedIn and
This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Participant to the requirements of applicable laws, rules and regulations, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement.
Executive Director, Corporate Communications
media@cloverbiopharma.com
Director, Investor Relations
investors@cloverbiopharma.com
Source:
2023 GlobeNewswire, Inc., source